Forbes: NewLimit among the longevity-biotech bets drawing billionaire capital

A Forbes piece published on 11 June 2026, "The New Billionaire Bet Isn't AI — It's Longevity Biotech", profiles NewLimit as one of the longevity-biotech companies attracting some of Silicon Valley's wealthiest investors. The article notes that longevity-biotech companies raised roughly $3.74bn across 49 financing events in Q1 2026, up 56% year on year, according to a Longevity.Technology analysis of PitchBook data.

NewLimit, the epigenetic-reprogramming company co-founded by Coinbase co-founder Brian Armstrong, is developing medicines designed to restore youthful cellular function rather than treating individual diseases one at a time. Co-founder and CEO Jacob Kimmel told Forbes the company built an AI system to prioritise the reprogramming medicines it tests in the lab, letting researchers "make discoveries more than twice as fast as relying on human intuition alone". He added that NewLimit is "initially developing medicines for diseases that share features with the aging process that's present in everyone", with hopes to expand to broader ageing populations.

NewLimit is named alongside fellow Tim Draper-backed longevity companies HeXem Bio and Colossal Biosciences. Tim Draper, an early investor in Tesla, SpaceX and Coinbase, has backed all three, telling Forbes that "aging is the one risk factor that affects 100% of the population" and "the largest addressable market that has ever existed".

Read more: Forbes